顺二氨二氯铂用于非小细胞肺癌患者的II期研究。
Phase II study of cis-diamminedichloroplatinum in patients with non-small cell lung cancer.
作者信息
Fujita J, Saijo N, Eguchi K, Shimizu E, Shinkai T, Tominaga K, Sasaki Y, Futami H, Sakurai M, Hoshi A
出版信息
Jpn J Cancer Res. 1985 May;76(5):420-3.
A phase II study of cis-diamminedichloroplatinum (CDDP, 80 mg/m2, every 3 weeks) was performed in patients with non-small cell lung cancer (NSCLC). The overall response rate to CDDP was 14% (6/42). In patients without prior chemotherapy, the response rate was 20% (2/10), and in patients with prior chemotherapy, the response rate was 13% (4/31). The major side effect was gastrointestinal toxicity. It was concluded that CDDP at a dose of 80 mg/m2 every 3 weeks is effective against NSCLC.
对非小细胞肺癌（NSCLC）患者进行了一项关于顺二氨二氯铂（CDDP，80mg/m²，每3周一次）的II期研究。CDDP的总缓解率为14%（6/42）。在未接受过化疗的患者中，缓解率为20%（2/10），在接受过化疗的患者中，缓解率为13%（4/31）。主要副作用是胃肠道毒性。得出的结论是，每3周一次剂量为80mg/m²的CDDP对NSCLC有效。
Zotero 插件